X	$\times\!\times\!\times\!\times\!\times\!\times$	
X		
X	$\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times$	
X	$\times\!\!\times\!\!\times\!\!\times\!\!\times$	
X	$\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times\!\!\times$	
\times	$\times\!\!\times\!\!\times\!\!\times\!\!\times$	


Collection Date: 11-05-2021 01:39 PM Sample Date: 11-05-2021 01:39 pm Report Date: 11-05-2021 05:41 PM

 $\langle XXXXXXXX$


	Age:70.90 Years Sex:FEMALE
	Ago .7 0.00 Todio Ock.T EIVIALE

Complete Blood Count	Result	Biological Reference Interval
(EDTA Whole Blood)		
Hemoglobin (Hb), EDTA whole blood	<u>11.80</u>	12.3 - 15.3 g/dL
Method: Photometry		
Total Leucocytes (WBC) count	<u>11,400</u>	4000-10000/μL
Method : Coulter Principle / Microscopy		
Platelet count	<u>457,000</u>	150000 - 450000 /μL
Method : Coulter Principle / Microscopy		
Red blood cell (RBC) count	4.18	4.10 - 5.10 x 10 <i>^</i> 6 /μL
Method: Coulter Principle		
PCV (Packed Cell Volume)	<u>35.70</u>	35.9 - 44.6 %
Method: Calculated		
MCV (Mean Corpuscular Volume)	85.40	80.0 - 96.0 fL
Method: Derived from RBC histogram		
MCH (Mean Corpuscular Hb)	28.30	27.5 - 33.2 pgms
Method: Calculated		
MCHC (Mean Corpuscular Hb Conc.)	<u>33.10</u>	33.4 - 35.5 g/dL
Method: Calculated		
RDW (RBC distribution width)	14.20	11.6 - 14.6 %
Method: Derived from RBC Histogram		
WBC Differential Count		
Method: VCSn / Microscopy / Calculated		
Neutrophils	72	40 - 80 %
Absolute Neutrophils	<u>8,208</u>	2000 - 7000 /μL
Eosinophils	1	1 - 6 %
Absolute Eosinophils	114	20 - 500 /μL
Basophils	0	0 - 2 %
Absolute Basophils	0	0 - 100 / <i>µ</i> L
Lymphocytes	23	20 - 40 %
Absolute Lymphocytes	2,622	1000 - 3000 /μL
Monocytes	4	2 - 10 %
Absolute Monocytes	456	200 - 1000 <i>lμ</i> L
-	#*-	

Page 1 of 7











Collection Date:
11-05-2021 01:39 PM
Sample Date:
11-05-2021 01:39 pm
Report Date:
11-05-2021 05:41 PM

F----

Age:70.90 Years Sex:FEMALE

Complete Blood Count Findings

R.B.C. : Normocytic, Normochromic

W.B.C. : Mild polymorphonuclear leucocytosis.

Platelets : Mild thrombocytosis.

Remark : SUGGESTED CLINICAL CORRELATION, B12, FOLIC ACID SUPPLEMENT & FOLLOW

UP.

-

•

-



Page 2 of 7

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

DIAGNOSTICS


BE SURE
BE WELL

Dr. Awanti GolwilkarMBBS, MD (Pathology)

rehendale

Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

Dr. Vinanti GolwilkarMBBS, MD (Pathology)



Collection Date:
11-05-2021 01:39 PM
Sample Date:
11-05-2021 01:39 pm
Report Date:
11-05-2021 05:41 PM

Age:70.90 Years Sex:FEMALE

Test DescriptionFerritin, serum by CMIA

Observed Value 118.00

Biological Reference Interval Female: 4.63-204 ng/mL

Ferritin is the major iron storage protein for the body. Ferritin is found chiefly in the cytoplasm of cells of the reticuloendothelial system and is a constituent of normal human serum. Generally the concentration of ferritin is directly proportional to the total iron stores in the body. There is a significant positive correlation between age and serum ferritin concentrations in females, but not in males. Patients with iron deficiency anemia have serum ferritin concentration approximately one-tenth of normal while patients with iron overload (hemochromatosis, hemosiderosis) have serum ferritin concentrations much higher than normal. Ferritin is a positive acute phase reactant in both adults and children, whereby chronic inflammation results in a disproportionate increase in ferritin in relation to iron reserves. Elevated ferritin is also observed in acute and chronic liver disease, chronic renal failure, and in some types of neoplastic disease.



Page 3 of 7

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

ehendale

DIAGNOSTICS
BE SURE
BE WELL

Dr. Awanti Golwilkar MBBS, MD (Pathology)



Collection Date:
11-05-2021 01:39 PM
Sample Date:
11-05-2021 01:39 pm

11-05-2021 01:39 pm Report Date: 11-05-2021 05:41 PM

F----

Age:70.90 Years Sex:FEMALE

Test Description Observed Value Biological Reference Interval

Enzymes:

LDH-Lactate Dehydrogenase, serum by UV Kinetic 175.00 81 to 234 U/Lt.



Page 4 of 7


"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

Carrying forward Dr. Ajit Golwilkar's legacy of Over Four Decades DIAGNOSTICS
BE SURE
BE WELL

Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

rehendale

MBBS, MD (Pathology)



Collection Date:
11-05-2021 01:39 PM
Sample Date:
11-05-2021 01:39 pm
Report Date:
11-05-2021 05:41 PM

Age:70.90 Years Sex:FEMALE

Observed Value

Biological Reference Interval

Coagulation:

D-Dimer, Citrate plasma

Test Description

614.60

0 to 500 ng/ml (FEU)

Upto four fold higher results may be observed in normal pregnancy.

Method: ELFA / CLIA

Kindly correlate clinically and follow up.

Note:

D-Dimer assay results may be affected by sample integrity, drug history and assay platform used. Kindly interpret the result in view of above factors and clinical details. In case of any discrepancy, repeat the estimation on fresh sample for confirmation.

D-Dimer is a fibrin degradation product.

D-Dimer is increased in: 1) DIC (Disseminated Intavascular Coagulation).

2) DVT (Deep Vein Thrombosis).

3) Hypercoagulable states.

4) Recent surgery, trauma, infection.

Increased levels may also be seen in the following conditions:

Liver disease, cardiac disease, rheumatoid arthritis, eclampsia, malignancy, hemolysis, lipemia & hyperbilirubinemia.

Please interpret with caution if patient is on anticoagulant therapy.



Page 5 of 7

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

ehendale

DIAGNOSTICS
BE SURE
BE WELL

Dr. Awanti Golwilkar
MBBS, MD (Pathology)

Dr. Vinanti Golwilkar

Carrying forward



Collection Date: 11-05-2021 01:39 PM Sample Date: 11-05-2021 01:39 pm Report Date: 11-05-2021 05:41 PM

Age:70.90 Years Sex:FEMALE

Test Description CRP(hs) - C- Reactive Protein high sensitivity **Observed Value**

1.83

Biological Reference Interval See clinical information below

Method: Nephelometry / Immunoturbidimetry

Clinical Information:

- 1. C-reactive protein (CRP) is a biomarker of inflammation. Plasma CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation.
- 2. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (i.e. normal) concentrations and enables a measure of chronic inflammation. It is recommended for cardiovascular risk assessment. Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.

Low cardiovascular risk : < 2.0 mg/L High cardiovascular risk : >/= 2.0 mg/L Acute inflammation : > 10.0 mg/L

3. A single test for high-sensitivity CRP (hs-CRP) may not reflect an individual patient's basal hs-CRP level. Repeat measurement may be required to firmly establish an individual's basal hs-CRP concentration. The lowest of the measurements should be used as the predictive value.

Reference: Mayo Medical Laboratories

ehendale


Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

Page 6 of 7 "Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"





MBBS, MD (Pathology)



Collection Date:
11-05-2021 01:39 PM
Sample Date:
11-05-2021 01:39 pm
Report Date:
11-05-2021 05:41 PM

Age:70.90 Years Sex:FEMALE

Test Description

Interleukin 6 (IL-6), serum by ECLIA

Observed Value

17.31

Biological Reference Interval Upto 7 pg/mL

Kindly correlate clinically and follow up.

Note:

IL-6 assay results may be affected by :

Sample integrity

Sample type (serum / plasma)

Treatment given

Assay platform used

Kindly interpret the result in view of the above factors and clinical details.

Please repeat on fresh sample if required. (Serum should be separated immediately after clotting).

- * Interleukin-6 (IL-6) is produced by different cell types, including macrophages, endothelial cells and T cells, in response to microbial invasion or other cytokines such as tumour necrosis factor (TNF).
- * IL-6 induces expression of C-reactive protein (CRP), fibrinogen and serum amyloid A also known as acute phase response.
- * Elevated IL-6 seen in:

Infections

Sepsis, septicimia

Rheumatoid arthritis

Systemic lupus erythematosus

Ankylosing spondylitis

Inflammatory Bowel Disease

* IL-6 concentration correlate with severity of sepsis.

End of Report

Dr.(Mrs.) Awanti Golwilkar Mehendale MBBS,MD(Path) Regn.No:2000/02/1052 A.G Diagnostics Pvt. Ltd.

Page 7 of 7
"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"



Carrying forward